Clinical Tools

Identify Best Practices for Screening and Diagnosis of GDM and T2DM

Clinical tools were developed with direction from a clinical advisory panel and contain guidance on best practices for screening and diagnosing your consumers with GDM and T2DM.

Timely Screening for GDM:

There are select groups of women including African American, American Indian or Alaska Native, Asian American, Hispanic or Latino, and Native Hawaiian or Pacific Islanders that are at greater risk for being diagnosed with GDM. Early identification can greatly improve the birth outcomes for these women. Additionally, consumers that meet the below criteria should also receive their OGTT early in pregnancy:

Previous history of GDM

Known impaired glucose metabolism

Previous birth of baby weighing more than 10 lbs

Obesity with BMI greater than 30

Polycystic Ovarian Syndrome

Consumers who don’t meet these criteria should receive their OGTT between 24 and 28 6/7 weeks gestation.

Postpartum Screening for T2DM:

ACOG currently recommends providing an OGTT screen between 6-12 weeks postpartum to identify a consumers risk for Type 2 Diabetes. Scheduling the screen either prior to delivery or while the consumer is in the hospital immediately following, may increase the likelihood of receipt of the screen. If the consumer screens negative for T2DM, she should follow up subsequently every three years to test her risk for it in the future. If upon receipt of the screen she is identified as being pre-diabetic that test should occur annually. However, if she tests positive for T2DM, she should establish regular appointments with a Primary Care Provider (PCP) and participate in self-management education and connect with a Dietician and/or Diabetes Educator to establish a care plan moving forward. Coordinating care among OBGYNs, PCPs, and Diabetes professionals is essential to ensure all future pregnancies are healthy and your consumer's condition is properly monitored.